Floatz logo

VINBLASTINE

TNBC - Triple-Negative Breast Cancer

Swiss Cancer InstituteSmall moleculePhase 2Active
CCC
51/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
73/ 100

Competitive context

57 Active assets in the TNBC - Triple-Negative Breast Cancer cohort.

Asset / SponsorPhaseRating
Toripalimab
Nanjing Leads Biolabs Co.,Ltd
Phase 3B
Metformin
The Methodist Hospital Research Institute
Phase 2B
Letrozole
NiKang Therapeutics, Inc.
Phase 2B
Fluzoparib
Tianjin Medical University Cancer Institute and Hospital
Phase 2B
Abemaciclib
UNC Lineberger Comprehensive Cancer Center
Phase 2B

View all 50 →

Same molecule, other indications

VINBLASTINE is also rated in:

renal pelvis/ureter urothelial carcinomaDormant
BBB
Indicative ·
73 / 100
View asset →
carcinoma of urethraDormant
BBB
Indicative ·
73 / 100
View asset →
Hodgkins lymphomaDormant
BBB
Indicative ·
72 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →